Thymosin Alpha-1 Calms Cytokine Storm in COVID-19 Blood Cells | Research

The takeaway

Thymosin alpha-1 (Tα1) mitigated cytokine storm responses in blood cells from COVID-19 patients, reducing excessive inflammatory signaling that drives severe disease.

Calms without suppressing
Tα1 reduced the excessive inflammatory response driving severe COVID-19 while maintaining immune function — modulation rather than suppression

What the researchers found

Thymosin alpha-1 mitigated cytokine storm in COVID-19 patient blood cells by reducing excessive inflammatory cytokine production without broad immunosuppression.

Why it matters

COVID-19 deaths are largely caused by cytokine storm, not the virus itself. A peptide that calms this storm without suppressing anti-viral immunity could save lives in severe cases.

The numbers in context

Cytokine signaling genes upregulated in COVID-19; Tα1 mitigated cytokine expression; CD8+ T cell subset specifically inhibited

How the study worked

Ex vivo study. Blood cells from COVID-19 patients treated with Tα1. Cytokine production measured. Inflammatory response modulation assessed.

Who was studied

Blood cells from COVID-19 patients treated ex vivo with thymosin alpha-1

What this study cannot tell us

Ex vivo study (blood cells in a dish, not whole patient). Small patient sample implied. Tα1 effects on intact immune system during active infection may differ. Clinical outcome data from Tα1 COVID treatment not provided.

How to read the evidence

Low evidence: ex vivo study on patient blood cells. Clinical efficacy not demonstrated.

When this study was published

Published 2021. Tα1 for COVID-19 has been studied in several clinical settings since.

The bigger picture

Tα1 is used clinically in several countries for immune modulation. Its ability to calm cytokine storms without broad immunosuppression makes it relevant not just for COVID-19 but for any condition involving hyperinflammatory immune responses.

Questions still open

Would Tα1 improve clinical outcomes when given to severe COVID patients?
How does Tα1 modulate inflammation without suppressing anti-viral immunity?
Could Tα1 treat cytokine storms from other causes (sepsis, CAR-T therapy)?

Common questions

What is thymosin alpha-1?

Tα1 is a naturally occurring peptide from the thymus gland that modulates immune responses. It's approved in some countries for hepatitis B/C and as an immune booster. It uniquely calms excessive inflammation while maintaining anti-pathogen immunity.

Can it help with COVID-19?

This lab study shows Tα1 reduces the cytokine storm driving severe COVID-19 in patient blood cells. Clinical studies are mixed but supportive. It's not a first-line COVID treatment but may help in severe cases with hyperinflammation.

Read the original research

Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients.

Open forum infectious diseases, 8(1), ofaa588

View on PubMed ↗Publisher’s paper ↗

Citation

Matteucci, Claudia; Minutolo, Antonella; Balestrieri, Emanuela; Petrone, Vita; Fanelli, Marialaura; Malagnino, Vincenzo; Ianetta, Marco; Giovinazzo, Alessandro; Barreca, Filippo; Di Cesare, Silvia; De Marco, Patrizia; Miele, Martino Tony; Toschi, Nicola; Mastino, Antonio; Sinibaldi Vallebona, Paola; Bernardini, Sergio; Rogliani, Paola; Sarmati, Loredana; Andreoni, Massimo; Grelli, Sandro; Garaci, Enrico. (2021). Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients.. Open forum infectious diseases, 8(1), ofaa588. https://doi.org/10.1093/ofid/ofaa588